Breast Cancer Meeting Highlights [Archive]

2023 European Breast Cancer Conference (0 replies)
2024 Miami Breast Cancer Conference Abstracts (0 replies)
2023 SABCS abstracts (1 replies)
2023 ASCO abstracts. (0 replies)
2022 SABCS Abstracts (2 replies)
2022 ASCO abstracts (0 replies)
2021 SABCS Abstracts (0 replies)
Top 5 Studies in Breast Cancer from ASCO 2021 (0 replies)
2021 ASCO abstracts. (0 replies)
ARX788: A potential new treatment after T-DM1, Enhertu. (0 replies)
Another new seems promising treatment (0 replies)
2020 ASCO abstracts (0 replies)
2020 SABCS abstracts (1 replies)
2019 SABCS Abstracts (0 replies)
Access 2019 ASCO Annual Meeting Proceedings – Breast Cancer Abstracts (0 replies)
HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab (0 replies)
SABCS 2018 abstracts available now. (0 replies)
SABCS 2017 abstracts (1 replies)
SABCS 2016 individual abstracts (0 replies)
ASCO 2015 Recap: Dr. Kimberly Blackwell Circles Back to HER2/ER Breast Cancer—Part 1 (0 replies)
ASCO 2015 Recap: Dr. Kimberly Blackwell Circles Back to HER2/ER Breast Cancer—Part 2 (0 replies)
SABCS 2014 All Abstracts (1 replies)
New ASCO Guidelines Address HER2-Positive Breast Cancer (5 replies)
Breast Cancer Preview: Critical Issues Resolved? (1 replies)
What's Hot at the ASCO Annual Meeting This Year? (1 replies)
We've come a long way, Baby! (2 replies)
Clinical impact of differential risk stratification by breast cancer index (BCI) vers (0 replies)
Characteristics of recurrence after completing adjuvant tamoxifen therapy for 5 years (1 replies)
Cardiac outcomes in women receiving aromatase inhibitors as adjuvant endocrine therap (0 replies)
Breast cancer in young women age 35 and under: Patterns of care and outcome. (0 replies)
Adjuvant palbociclib (P) plus endocrine therapy (ET) (0 replies)
Hey! Cost Effectiveness for our Canadian friends . . . (0 replies)
oral bisphosphonate treatment on bone mineral density in osteopenic women receiving a (0 replies)
AE37 vaccine (0 replies)
Breast cancer subtypes according to body mass index and insulin resistance. (0 replies)
Association between visceral adiposity, BMI, and clinical outcomes in postmenopausal (0 replies)
Association between the expression of hormone receptors and HER2/Neu in early breast (0 replies)
Association between androgen receptor (AR) expression, Ki-67, and the 21-gene recurre (0 replies)
Arobase: A phase III trial of exemestane (Exe) and bevacizumab (BEV) as maintenance t (0 replies)
An immune-related signature for prediction of risk of late recurrences beyond prolife (0 replies)
Advanced luminal breast cancer: Who receives chemotherapy as first-line systemic trea (0 replies)
Adjuvant trastuzumab in the treatment of small HER2-positive tumors: A single institu (0 replies)
Regulation of C-terminal and N-terminal fragments of HER2 by mRNA. (0 replies)
Projecting the cost-effectiveness of pertuzumab with trastuzumab and docetaxel in the (0 replies)
Profiling of signaling pathways in live tumor cells to assess drug mechanism of actio (0 replies)
Primary analysis of the prospective, randomized, single-blinded phase II trial of AE3 (0 replies)
Phase I/II study of adoptive T-cell therapy following in vivo priming with a HER2/neu (0 replies)
Efficacy of adjuvant trastuzumab (T) compared with no T for patients (pts) with HER2- (0 replies)
Comparison of recurrent and nonrecurrent breast cancer patients undergoing AE37 pepti (0 replies)
Comorbidity, metastases, and survival in women with metastatic breast cancer (mBC) re (0 replies)
Changing pattern for HER2 positivity due to updated ASCO/CAP guidelines for HER2 test (0 replies)
Upcoming Abstracts for Her2 Breast Cancer ASCO 2014 (7 replies)
Risk of CNS relapse following adjuvant trastuzumab therapy (0 replies)
Improved clinical outcomes associated with statin use during adjuvant chemotherapy (0 replies)
Sexual function, sexual activity and quality of life in women with breast cancer (0 replies)
The Will Rogers phenomenon in breast cancer (0 replies)
Seasonal variation in onset of inflammatory breast cancer: Evidence of an infectious (0 replies)
Redefining the breast tumor margin through genomics of the tumor-stromal interaction (0 replies)
Cutaneous toxicity and recovery: Is there a difference between breast cancer patients (0 replies)
Permanent chemotherapy induced alopecia in early breast cancer patients (0 replies)
Impact of estrogen receptor (ER) and HER2 co-expression on breast cancer characterist (0 replies)
HER2/HR positive early breast cancer patients have the highest disease-free survival (5 replies)
Association between metformin use and improved survival in breast cancer patients (0 replies)
HER2 copy number on FISH as a predictor of disease severity in HER2- breast cancer (0 replies)
Clues to the metabolic fingerprint of inflammatory breast cancer (0 replies)
The clinicopathological features of androgen receptor expression in primary HER2+ bc (1 replies)
Identification of synergistic drug combination for HER2 positive breast cancer (0 replies)
Chronic inflammation and the development of breast cancer (0 replies)
Resveratrol blocks the protumorigenic effects of obesity in a postmenopausal bc (0 replies)
Mammographic microcalcifications and breast cancer tumorigenesis (0 replies)
Whole genome methylation patterns in male and female breast cancer – Unexpected findi (0 replies)
Intermittent letrozole as adjuvant treatment in postmenopausal hr+ bc (0 replies)
Comparison of cardiovascular outcomes in postmeno women treated w/AI's vs. Tamoxifen (0 replies)
Risk of recurrence following 5 years of adjuvant hormone therapy for hr+ ebc (0 replies)
The therapeutic sensitivity of ER+/Her2+ breast cancer cells is attenuated in 3D matr (0 replies)
NSAID use attenuates breast cancer recurrence in obese women (0 replies)
PIK3CA mutations and/or low PTEN predict resistance to combined Herceptin/Tykerb (0 replies)
Skin care tips during radiation - from the Mayo Clinic (0 replies)
Efficacy of scalp cryotherapy in preventing alopecia among patients with breast cance (3 replies)
Long-term quality of life of breast cancer survivors (0 replies)
Use of intravaginal 17-β estradiol to improve sexual function in AI patients (0 replies)
Bridging to survivorship in breast cancer: How BMI weighs in (0 replies)
Discussions regarding reproductive and sexual health among young adult survivors (0 replies)
Nonalcoholic fatty liver disease after adjuvant therapy in nonmetastatic breast cance (0 replies)
Actigraphy measured sleep disruption as a predictor of survival in advanced bc (0 replies)
Perceived versus measured functional vaginal capacity in cancer patients (0 replies)
Taking control of cancer: Why women are choosing mastectomy (0 replies)
Arrhythmias during and after zoledronic acid infusion patients with bone metastasis (0 replies)
Continuing to work while receiving cancer treatment: A financial or a symbolic issue? (0 replies)
Patient perceptions about potential side effects and benefits from chemotherapy agent (0 replies)
Effect of dormant cancer cells on angiogenesis after resisting chemotherapy (0 replies)
Antibiotic exposure and risk of breast cancer: A causal association or a skyfall? (0 replies)
The role of chemotherapy in ER+ and HER2+ breast cancer patients over age 70 (0 replies)
The relationship between serum vitamin D levels and breast cancer prognosis (0 replies)
Chemoprevention of cancer with metformin: A meta-analysis (0 replies)
Breast cancer mortality among users of cholesterol-lowering drugs (0 replies)
Outcomes of HER2-positive nonmetastatic breast cancer patients w/wo BRCA mutations (0 replies)
Distinctive lipid profiles of human breast cancer and adjacent normal tissues (0 replies)
Does radiation therapy increase late cardiac death in patients with left bc? (1 replies)
Impact of delaying initiation of adjuvant chemotherapy in breast cancer patients (0 replies)
A gene expression profile indicative of early stage HER2 tyrosine kinase inhibitor (0 replies)
Prognostic value of HER2 on breast cancer survival (0 replies)
Brain and tumor penetration of carbon-11–labeled lapatinib ([11C]Lap) (0 replies)
HER2-positive disseminated tumor cells in bone marrow of patients with HER2- tumors (0 replies)
When less is better: Safety and efficacy of combination of trastuzumab and metronomic (0 replies)
The prognostic role of androgen receptor in early-stage breast cancer patients (0 replies)
Long-term (8 years) assessment of trastuzumab-related cardiac events in the HERA tria (0 replies)
Demographic and clinicopathologic characteristics in patients with invasive bc (0 replies)
Long-term survival of women with breast cancer with ≥10 lymph nodes at diagnosis (0 replies)
Evaluation of factors related to late recurrence (later than 10 years after bc dx) (0 replies)
Prediction of early and late distant recurrence in early-stage breast cancer with BC (0 replies)
ER as a predictor of early breast cancer (EBC) outcomes in patients (0 replies)
A study on the prevalence of HER2 genetic heterogeneity and its impact on bc survival (0 replies)
Are aromatase inhibitors (AIs) optimal therapy in obese ER+ BC? (0 replies)
Relationship of tumor and stromal autophagy and endocrine responsiveness in bc (0 replies)
Comparative analysis of bone marrow micrometastases with sentinel lymph node status (0 replies)
Periodontal health in early-stage postmenopausal breast cancer survivors on AIs (0 replies)
CYP2D6 phenotype and Tamoxifen dosing (0 replies)
Extended adjuvant tamoxifen for early breast cancer: A meta-analysis (0 replies)
Patients Carrying CYP2C8*3 Are at Increased Risk of Paclitaxel-Induced Neuropathy (0 replies)
Whole-Genome Progression of Breast Cancer from Early Neoplasia to Invasive Carcinoma (0 replies)
Effect of Metformin on Apoptosis in a Presurgical Trial in Non-Diabetic BC Patients (0 replies)
The Effect of HER2 Expression on Luminal A Breast Tumors (0 replies)
Inhibition of mTOR and FASN Overcome Acquired Resistance to Traztuzumab (0 replies)
Disease-Related Outcomes with Adjuvant Chemotherapy in HER2+ or TN small tumors (0 replies)
Prognosis of Metastatic Breast Cancer Subtypes: ER+/HER2+ Is Associated with the Most (0 replies)
Leptin and Leptin Receptor Expression in Human Breast Cancer (0 replies)
Estradiol Levels in Postmenopausal ER+/PR+ > Than in Postmenopausal ER+/PR- BC (0 replies)
Vitamin D Induces Expression of Estrogen Receptor and Restores Endocrine Therapy Resp (0 replies)
Identification of ErbB2 Function in the Heart (0 replies)
Selective Crossover in Randomized Trials of Adjuvant Trastuzumab (0 replies)
The Effect of Weight Change on Breast Adipose and Dense Tissue (0 replies)
Hormone Replacement Therapy, Is There an Increased Risk of In Situ Breast Cancer? (0 replies)
Diabetes Increases the Risk of Breast Cancer (0 replies)
Novel Insight into the Tumor “flare” Phenomenon and Lapatinib Resistance (0 replies)
Survival Impact of Early Detection of Recurrence after Surgery in Early Breast Cancer (0 replies)
Impact of Body Mass Index (BMI) on the Efficacy of Aromatase Inhibitors (0 replies)
Efficacy and Safety of Scalp Cooling (SC) Treatment for Alopecia Prevention (0 replies)
Ultra-Low Dose Vaginal Estriol and Lactobacillus Acidophilus (Gynoflor®) (0 replies)
Limited Absorption of Low Dose 10µg Intravaginal 17-β Estradiol (Vagifem®) (0 replies)
Weight Change and Risk of Incident Diabetes after Breast Cancer (0 replies)
Effects of Chemotherapy on the Ovary: What You Didn't Know (0 replies)
Estrogen Receptor Positivity: 10% or 1%? (0 replies)
Modeling Cancer Recurrence and the Therapeutic Effect of Adjuvant Systemic Therapy (0 replies)
Her2 therapy for Her2 "negative"? (1 replies)
low dose estradiol for AI resistance (0 replies)
Determing support for the stigma of MBC (0 replies)
Paget's Information from SABCS abstract (1 replies)
Vaccine significantly reduces relapse in Her2+ and Her2- (0 replies)
P5-16-05 The combination of trastuzumab and HER2-directed peptide vaccines is safe in (0 replies)
P5-16-02 Final Results of the Phase I/II Trials of the E75 Adjuvant Breast Cancer Vac (0 replies)
Link to the 2012 SABCS Abstract book (1 replies)
Molecular Profiling Doesn't Trump Standard Pathology (5 replies)
Prediction of late metastasis in node-negative breast cancer (0 replies)
Association of core needle biopsies with increase in metastatic dissemination of bc (0 replies)
Coping with the burden of taste alteration, a toxicity of taxane-based chemotherapy (0 replies)
Low-level laser therapy for chemotherapy-induced peripheral neuropathy (0 replies)
Sexual functioning in young women with breast cancer (0 replies)
The use of the word “cure” in oncology (0 replies)
Oncologists' and primary care providers' awareness of late effects of cancer treatmen (0 replies)
Comparison of primary care providers’ and oncologists’ preferences for survivor care (0 replies)
Response of HER2+ breast cancer patients to allogeneic cell immunotherapy (0 replies)
Safety and long-term maintenance of anti-HER2 immunity following booster inoculations (0 replies)
Incidence and implications of oligometastatic breast cancer (0 replies)
Prognostic impact of weight change during chemotherapy (0 replies)
Efficacy of low-dose capecitabine in metastatic breast cancer (0 replies)
Low-dose, short-course sunitinib may normalize tumor vasculature & improve chemo effi (0 replies)
Relationship between cancer and allergy (0 replies)
Changes in glucose, insulin, and insulin resistance from presurgery to post adjuvant (0 replies)
Significance of chromosome 17 polysomy in breast cancer (0 replies)
Non-breast solid malignancies among breast cancer survivors (0 replies)
Statin use decreased bone mets (0 replies)
The effect of cholesterol depletion in resistant breast cancer cells (0 replies)
Variations of the ER, PR, and HER2 expression status according to operation day (0 replies)
Does obesity change the effect of AIs on estradiol, leptin, insulin, and IGF-1 serum (0 replies)
Correlation between weight at diagnosis, weight gain after breast cancer & recurrence (1 replies)
The role of Ki-67 in molecular breast cancer classification (0 replies)
Prognostic factor Ki67 for breast cancer patients in each subgroup (0 replies)
Impact of exogenous female hormone use on BC recurrence as assessed by Oncoty (0 replies)
Estrogen receptor in HER2-positive early breast cancer: Two different diseases? (0 replies)
Long-term follow-up of patients with durable complete response after chemo/H for mbc (0 replies)
Incidence and risk of brain mets as site of first recurrence after adj Herceptin (0 replies)
Quantitative HER2 levels and steroid receptor expression in primary bc and brain mets (0 replies)
Impact of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2+ bc (0 replies)
Impact of hormone receptor status on patterns of recurrence in Her2+ bc (0 replies)
Impact of adjuvant trastuzumab on outcomes of HER2+ mbc (0 replies)
Tumor PIK3CA mutations, lymphocyte infiltration, and recurrence-free survival (RFS) (0 replies)
13-gene signature to predict rapid development of brain mets in advanced Her2+ bc (0 replies)
The Impact of Primary Tumor Resection on the Survival of Patients with Stage IV BC (0 replies)
Multicenter Results of Scalp Cooling To Prevent Chemotherapy-Induced Alopecia (0 replies)
Survival in Women with Breast Cancer Who Used or Did Not Use Scalp Cooling (0 replies)
A Population Level Assessment of Emergency Room Visits and Hospitalizations for chemo (0 replies)
Patients' Views about How Oncologists Should Explain Prognosis in Advanced Cancer (0 replies)
Stage IV at Presentation – Are HER2 Positive Tumors Overrepresented? (0 replies)
Mammographic Microcalcifications and Breast Cancer Tumorigenesis (6 replies)
Preoperative Endocrine Therapy: New Approaches (0 replies)
Translational Science Insights Relevant to Effects of Diet, Exercise, and Metformin (0 replies)
HIF-1, Metabolism, and Breast Cancer Metastasis (0 replies)
Extrinsic and Intrinsic Force Regulation of Breast Cancer Progression and Treatment (0 replies)
Is Cranial MRI Necessary for Staging of Asymptomatic HER2+ BC Patients? (0 replies)
The Shifting Landscape of Metastatic Breast Cancer to the CNS (0 replies)
Brain Metastasis Free Survival (BMFS) Differs between Breast Cancer Subtypes (0 replies)
Incidence Rate of Asymptomatic Brain Metastases in Patients with HER2+ MBC (0 replies)
Trastuzumab Does Not Increase the Incidence of CNS Relapses in HER2+ EBC (0 replies)
Risk Factors for Relative Weight Gain >10% in Breast Cancer Survivors (0 replies)
Thyroid Disease Is Associated with Breast Cancer: A Meta-Analysis (2 replies)
CA15-3 Adds Prognostic Information in “Luminal” Type Breast Cancer (0 replies)
Systemic Cholesterol promotes Breast Tumor Aggressiveness (0 replies)
Influence of the Progesterone Receptor on Prognosis (1 replies)
PR- Predicts Poor Outcome in ER+ NN BC (0 replies)
Metformin for Breast Cancer Prevention: A Pilot Study (0 replies)
Intermittent Dietary Carbohydrate Restriction Enables Weight Loss (0 replies)
Change in Carbohydrate Intake and Breast Cancer Prognosis (0 replies)
Are Single Node Metastases More Common in Patients with Breast Cancer in the SNB Era? (0 replies)
Increased cellular expression activity of minimal residual disease in bc post-surgery (0 replies)
Patterns of Distant Metastasis According to the Molecular Subtypes (0 replies)
Tumor Heterogeneity and Metastasis (0 replies)
Macrophages as Novel Targets for Therapy in Breast Cancer (0 replies)
Making the Case for Fucose-Depleted Trastuzumab (0 replies)
Systemic Adjuvant Treatment of T1a and T1b N0M0 HER2+ Breast Carcinomas (0 replies)
Relationship of meno symptoms & arthralgia to OS in endocrine therapy (0 replies)
Influence of Delayed Zoledronic Acid on DFS in post-meno, HR+ BC (0 replies)
Prognostic Value of HER2+/ER- in small NN tumors (0 replies)
Pooled Analysis of Outcomes of T1a/bN0, HER2-Amplified Breast Cancer (0 replies)
Correlation between Quantitative HER2 Protein Expression and Risk of Brain Metastases (0 replies)
Correlation between BMI and Clinical Outcome of Patients with Early Stage HER2+ BC (0 replies)
Genomic Instability in Breast Cancers from Atomic Bomb Survivors (0 replies)
Acquired Tamoxifen Resistance Promotes Angiogenic Responses in ER+ BC Cells (0 replies)
Novel Pathways Underlying the Initiation and Transition of DCIS to IDC of HER2+ BC (0 replies)
NSAID Analgesic Ketorolac Used Perioperatively May Suppress Early BC Relapse (0 replies)
Cognitive Function and Reproductive Hormones in Women Receiving Anastrozole (0 replies)
Sexual Dysfunction in Women with Early Stage Breast Cancer on Endocrine Therapy (0 replies)
Sexual Dysfunction in Premenopausal Women with Breast Cancer: Prevalence and Severity (0 replies)
HER-2 Testing and Treatment – Is Age a Factor? (3 replies)
Adjuvant Trastuzumab Effect on HER2+ Breast Cancers According to Hormonal Status (0 replies)
Inhibition of Autophagy Suppresses Intrinsic Resistance of Her2+ BC to therapies (0 replies)
Complete Pathological Response of DCIS after Treatment with Neoadjuvant Herceptin (0 replies)
Combined Targeting of the PI3K Pathway and HER2 Overcomes Trastuzumab Resistance (0 replies)
Pregnancy during and Following Adjuvant Trastuzumab (0 replies)
Fetal Microchimerism and In Situ Breast Cancer (0 replies)
Prevalence of Germline TP53 Mutations in Young Women with HER2-Positive Breast Cancer (0 replies)
HDL-Cholesterol and Low-Penetrance Gene CYP17 rs2486758 Influence Daily Estrogen Leve (0 replies)
Assessment of the impact of ineffective treatments on metastatic breast cancer (0 replies)
Treatment Patterns and Clinical Outcomes in Elderly Patients with HER2+ MBC (0 replies)
Aspirin Exposure and Nodal Status at Diagnosis in Women with Stage I-III Breast Cance (0 replies)
Pattern of Cardiac Monitoring and Risk of Trastuzumab Associated-Cardiac Dysfunction (0 replies)
Age and Survival in Women with Early Stage BC: An Analysis Controlling for subtype (0 replies)
Obesity, Adjuvant Therapy, and Survival Outcomes in Early-Stage Breast Cancer (0 replies)
Huge Improvement in Relapse-Free Breast Cancer Survival over the Last 25 Years (0 replies)
Consistent High False Negative Rate of HER2 qRT-PCR of Oncotype DX® (0 replies)